Samsung Health logo / Courtesy of Samsung Electronics
Samsung Electronics is teaming up with Massachusetts General Hospital and Harvard Medical School researchers to study whether its Galaxy Watch can help patients taking popular GLP-1 weight-loss drugs avoid one of the treatment’s most troubling side effects: muscle loss.
The Korean technology giant said Thursday that it is conducting a joint study with the Diabetes Center at Massachusetts General Hospital, widely known as MGH, to track physical changes in patients using GLP-1 medications through data collected by the Galaxy Watch8 and Samsung Health platform.
As GLP-1 drugs gain explosive popularity worldwide for obesity treatment and chronic disease management, doctors have increasingly raised concerns about side effects including muscle reduction, digestive complications and rapid weight gain after treatment ends.
The study will examine whether daily biometric data collected through wearable devices can help patients preserve muscle mass during treatment.
